When assessing composite adverse outcomes (death, worsening HF, or VT), the GH group exhibited substantially fewer events (27 vs. 46), further supporting its safety and potential efficacy [10,11,12,13,14,15,16,17,18,19,20,21,22,23,24]. The gene discussed is GH1; the disease is hydrops fetalis.